Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Arcus Biosciences Inc’s stock clocked out at $11.97, down -3.86% from its previous closing price of $12.45. In other words, the price has decreased by -$3.86 from its previous closing price. On the day, 0.53 million shares were traded. RCUS stock price reached its highest trading level at $12.52 during the session, while it also had its lowest trading level at $11.89.
Ratios:
To gain a deeper understanding of RCUS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.23 and its Current Ratio is at 5.23. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on October 21, 2024, initiated with a Neutral rating and assigned the stock a target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.
On November 18, 2022, BofA Securities started tracking the stock assigning a Neutral rating and target price of $33.BofA Securities initiated its Neutral rating on November 18, 2022, with a $33 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 31 ’24 when Goeltz II Robert C. sold 3,594 shares for $15.00 per share. The transaction valued at 53,910 led to the insider holds 60,138 shares of the business.
Goeltz II Robert C. bought 3,594 shares of RCUS for $53,910 on Dec 31 ’24. On Dec 02 ’24, another insider, Azoy Alexander, who serves as the Chief Accounting Officer of the company, sold 201 shares for $15.32 each. As a result, the insider received 3,079 and left with 19,070 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1095393920 and an Enterprise Value of 85393960. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.16 while its Price-to-Book (P/B) ratio in mrq is 1.94. Its current Enterprise Value per Revenue stands at 0.325 whereas that against EBITDA is -0.297.
Stock Price History:
The Beta on a monthly basis for RCUS is 1.33, which has changed by -0.21992481 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $20.31, while it has fallen to a 52-week low of $12.26. The 50-Day Moving Average of the stock is -19.37%, while the 200-Day Moving Average is calculated to be -23.88%.
Shares Statistics:
It appears that RCUS traded 654.65K shares on average per day over the past three months and 591420 shares per day over the past ten days. A total of 91.50M shares are outstanding, with a floating share count of 48.88M. Insiders hold about 46.59% of the company’s shares, while institutions hold 54.48% stake in the company. Shares short for RCUS as of 1738281600 were 6379345 with a Short Ratio of 12.60, compared to 1735603200 on 7751443. Therefore, it implies a Short% of Shares Outstanding of 6379345 and a Short% of Float of 14.38.
Earnings Estimates
Investors are keenly observing as 6.0 analysts analyze and rate the current performance of Arcus Biosciences Inc (RCUS) in the stock market.The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.89 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$2.45 and -$3.65 for the fiscal current year, implying an average EPS of -$3.16. EPS for the following year is -$3.66, with 7.0 analysts recommending between $0.06 and -$5.43.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $31.31M. It ranges from a high estimate of $37M to a low estimate of $25M. As of the current estimate, Arcus Biosciences Inc’s year-ago sales were $31MFor the next quarter, 8 analysts are estimating revenue of $40.7M. There is a high estimate of $65M for the next quarter, whereas the lowest estimate is $25M.
A total of 10 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $272M, while the lowest revenue estimate was $244M, resulting in an average revenue estimate of $260.53M. In the same quarter a year ago, actual revenue was $117MBased on 10 analysts’ estimates, the company’s revenue will be $215.85M in the next fiscal year. The high estimate is $577.35M and the low estimate is $30M.
